Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 1052-1060

  Zhang, Muchun ^a,b   Wang, Jinhui ^a,b   Li, Chang ^b,c   Hu, Ningning ^b,c   Wang, Kai ^b,c   Ji, Huifan ^a,b   He, Dongyun ^a,b   Quan, Chengshi ^d   Li, Xiao ^b,d   Jin, Ningyi ^b   Li, Yulin ^d  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c Key Laboratory of Jilin Province for Zoonosis Prevention and Control   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Apoptin gene; PC 3 and RM 1 cells; Prostate cancer; Recombinant adenovirus

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ACRIDINE ORANGE; ADENOVIRUS CMV APOPTIN PROTEIN; ADENOVIRUS CMV EGFP PROTEIN; ADENOVIRUS HTERT E1A APOPTIN PROTEIN; ADENOVIRUS HTERT E1A EGFP PROTEIN; APOPTIN; E1A PROTEIN; ETHIDIUM BROMIDE; LIPOCORTIN 5; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; LIFE EXTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CAPSID PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKEN ANEMIA VIRUS; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RANDOM ALLOCATION;

EID: 84873662059     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1783     Document Type: Article

References (33)

1. Damber JE and Aus G: Prostate cancer. Lancet 371: 1710-1721, 2008. (Pubitemid 351671887)
2. Burton AJ, Tilling KM, Holly JM, Hamdy FC, Rowlands MA, Donovan JL and Martin RM: Metabolic imbalance and prostate cancer progression. Int J Mol Epidemiol Genet 1: 248-271, 2010.
3. Di Lorenzo G and De Placido S: Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol 19: 11-34, 2006.
4. Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D and Fisher PB: Developing an effective gene therapy for prostate cancer: new technologies with potential to translate from the laboratory into the clinic. Discov Med 11: 46-56, 2011.
5. Hu W and Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4: 721-729, 2003. (Pubitemid 37527207)
6. Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D and Noteborn MH: Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem 278: 27729-27736, 2003. (Pubitemid 36899962)
7. Oro C and Jans DA: The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets 5: 179-190, 2004. (Pubitemid 38279416)
8. Poon IK, Oro C, Dias MM, Zhang J and Jans DA: Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res 65: 7059-7064, 2005. (Pubitemid 41161232)
9. Li X, Jin N, Mi Z, Lian H, Sun L and Zheng H: Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Int J Cancer 119: 2948-2957, 2006. (Pubitemid 44846250)
10. Maioli E, Torricelli C, Fortino V, Carlucci F, Tommassini V and Pacini A: Critical appraisal of the MTT assay in the presence of rottlerin and uncouplers. Biol Proced Online 11: 227-240, 2009.
11. Mitrovic T, Stamenkovic S, Cvetkovic V, Tosic S, Stankovic M, Radojevic I, Stefanovic O, Comic L, Dacic D, Curcic M and Markovic S: Antioxidant, antimicrobial and antiproliferative activities of five lichen species. Int J Mol Sci 12: 5428-5448, 2011.
12. Baskic D, Popovic S, Ristic P and Arsenijevic NN: Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using Annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int 30: 924-932, 2006. (Pubitemid 44635308)
13. Ding W, Ju S, Jiang S, Zhu L, Wang Y and Wang H: Reduced APRIL expression induces cellular senescence via a HSPGdependent pathway. Pathol Oncol Res 15: 693-701, 2009.
14. Candal E, Anadon R, DeGrip WJ and Rodriguez-Moldes I: Patterns of cell proliferation and cell death in the developing retina and optic tectum of the brown trout. Brain Res Dev Brain Res 154: 101-119, 2005. (Pubitemid 40023135)
15. Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK and Los M: Modeling of molecular interaction between apoptin, BCR-Abl and CrkL - an alternative approach to conventional rational drug design. PLoS One 7: e28395, 2012.
16. Adair BM: Immunopathogenesis of chicken anemia virus infection. Dev Comp Immunol 24: 247-255, 2000. (Pubitemid 30136304)
17. Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F and Schulze-Osthoff K: Apoptin, a tumor-selective killer. Biochim Biophys Acta 1793: 1335-1342, 2009.
18. van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH and Hoeben RC: Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 9: 53-61, 2002. (Pubitemid 34052854)
19. Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH and Cornelis JJ: Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther 8: 958-965, 2001. (Pubitemid 33140314)
20. Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJ, van der Eb AJ, Hoeben RC and Noteborn MH: Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 6: 882-892, 1999. (Pubitemid 29243663)
21. Heilman DW, Teodoro JG and Green MR: Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/ cyclosome to PML bodies. J Virol 80: 7535-7545, 2006. (Pubitemid 44092575)
22. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S and Los M: Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci 118: 4485-4493, 2005. (Pubitemid 41556346)
23. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T and Los M: Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 5: 10-19, 2006. (Pubitemid 43234971)
24. Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S, Jans DA, Schulze-Osthoff K and Los M: Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene 27: 3060-3065, 2008. (Pubitemid 351668005)
25. Wagstaff KM and Jans DA: Nuclear drug delivery to target tumour cells. Eur J Pharmacol 625: 174-180, 2009.
26. Jiang J, Cole D, Westwood N, Macpherson L, Farzaneh F, Mufti G, Tavassoli M and Gaken J: Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin. Cancer Res 70: 7242-7252, 2010.
27. Los M, Maddika S, Erb B and Schulze-Osthoff K: Switching Akt: from survival signaling to deadly response. Bioessays 31: 492-495, 2009.
28. Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, Schulze-Osthoff K and Los M: Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 29: 1235-1248, 2009.
29. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
30. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG and Au JL: Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 63: 579-585, 2003. (Pubitemid 36158134)
31. Wirth T, Kuhnel F and Kubicka S: Telomerase-dependent gene therapy. Curr Mol Med 5: 243-251, 2005. (Pubitemid 40601653)
32. Hernandez-Alcoceba R, Pihalja M, Qian D and Clarke MF: New oncolytic adenoviruses with hypoxia- and estrogen receptorregulated replication. Hum Gene Ther 13: 1737-1750, 2002. (Pubitemid 35191748)
33. Kurihara T, Brough DE, Kovesdi I and Kufe DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106: 763-771, 2000.